Testing for drug resistance in tuberculosis using nanoreactor beads
Nanoreactor beads for POC TB resistance testing
This study is working on a quick and easy test that can help doctors find out if tuberculosis (TB) is resistant to treatment by checking for specific changes in the bacteria, so patients can get the right care within just 30 minutes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10982504 on NIH RePORTER |
What this research studies
This research aims to develop a rapid and sensitive point-of-care test that can detect drug resistance in tuberculosis (TB) by identifying specific mutations in the Mycobacterium tuberculosis bacteria. Utilizing advanced nanoreactor bead chemistry and a specialized testing platform, the system will provide results within 30 minutes, allowing for immediate treatment decisions. The approach combines digital and real-time PCR technologies to ensure accurate detection of multiple resistance mutations, enhancing the ability to manage TB effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suspected of having tuberculosis, particularly those with a history of treatment failure or exposure to drug-resistant strains.
Not a fit: Patients who do not have tuberculosis or those with non-infectious conditions will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate diagnosis of drug-resistant tuberculosis, improving treatment outcomes for patients.
How similar studies have performed: Previous research has shown success in developing rapid diagnostic tests for tuberculosis, indicating a promising avenue for this novel approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Alland, David — Rutgers Biomedical and Health Sciences
- Study coordinator: Alland, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.